Skip to main content

CombinatoRx and Charley’s Fund/Nash Avery Foundation Collaborate to Develop Novel Agents for Duchenne Muscular Dystrophy

By November 8, 2007December 20th, 2022News
    $3 Million to Fund Drug Discovery and Product Development Program

        -- Novel Mechanism Combination Pharmaceuticals to Treat
    Debilitating Muscle Wasting Disease with 100% Mortality Rate -

CAMBRIDGE, Mass. & SOUTH EGREMONT, Mass.–(BUSINESS WIRE)–Nov. 8, 2007–CombinatoRx, Incorporated (NASDAQ: CRXX) today announced a research collaboration with Charley’s Fund and the Nash Avery Foundation, both nonprofit organizations founded to support Duchenne muscular dystrophy (DMD) research. The collaboration will seek to identify novel disease-modifying multi-targeted treatments for DMD, the most common form of muscular dystrophy.

“DMD is a devastating muscle-wasting disease for which there are no effective treatment options,” said Benjamin Seckler, M.D., president of Charley’s Fund. “We are excited about the possibility of developing new medicines built from synergistic combinations of approved drugs. This unique approach to drug development could significantly compress the timeline for getting new therapies into the clinic. We continue to work on many levels and to collaborate with leading non-profit, academic, and industry organizations, such as CombinatoRx, in seeking an effective treatment or cure for DMD.”

“We are pleased to have been selected by Charley’s Fund and the Nash Avery Foundation to leverage our combination High Throughput Screening (cHTS(TM)) technology to discover novel multi-target therapeutics to address DMD, a disease with critically high unmet medical need,” commented Daniel Grau, Chief Operating Officer. “This collaboration continues to build our pipeline and R&D capability in the degenerative disease space where there is significant opportunity to create important medicines.”

The collaboration will focus on the use of the CombinatoRx cHTS(TM) drug discovery technology to identify disease-modifying multi-targeted DMD therapeutic candidates. CombinatoRx will be screening for synergistic activity in both DMD-relevant in vitro assays and assays that have broadly implicated mechanisms beyond DMD. Under the agreement, CombinatoRx receives up to $3 million in research funding, owns new intellectual property generated during the collaboration and has full worldwide commercialization rights to all product candidates.

About Duchenne Muscular Dystrophy

DMD is the most common fatal genetic disorder to affect children around the world. Children with DMD cannot produce dystrophin, a protein necessary for muscle strength and function. As a result, every skeletal muscle in the body deteriorates. There is no cure or effective treatment for DMD. Approximately one in 3,500 boys is born with DMD, and an estimated 15,000 to 20,000 children are afflicted in the United States alone.

About Charley’s Fund

Charley’s Fund is a not-for-profit foundation that finances therapeutics development for Duchenne muscular dystrophy. The foundation’s mission is to expedite a treatment or cure in time to help this generation of children who suffer from DMD. Charley’s Fund targets translational research–research that moves science from the lab into human clinical trials. The 501(c)(3) public charity was co-founded in 2004 by Benjamin Seckler, M.D. and Tracy Kramer Seckler, whose 6-year-old son Charley has Duchenne muscular dystrophy. To learn more about Charley’s Fund, visit

About Nash Avery Foundation

The Nash Avery Foundation is a not-for-profit private foundation that is focused on financially supporting programs that will slow and eventually stop Duchenne muscular dystrophy. Nash Avery Foundation was founded by Angela and Tom Wicka after their son Nash was diagnosed with DMD. The Foundation believes that the solution in stopping this disease will come from a combination of well funded science and getting talented people focused on this disease.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive Phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its planned research efforts relating to Duchenne’s muscular dystrophy, its collaboration research agreement with an affiliate of Charley’s Fund, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx and its research in the field of Duchenne’s muscular dystrophy involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology as applied to Duchenne’s muscular dystrophy, the Company’s ability to obtain additional financing or funding for its research and development and those other risks that can be found in the “Risk Factors” section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

(c) 2007 CombinatoRx, Incorporated. All rights reserved.

    CONTACT: CombinatoRx Contact:
             CombinatoRx, Incorporated
             Robert Forrester, 617-301-7100
             EVP, Chief Financial Officer
             Gina Nugent, 617-301-7099
             VP, Corporate Communications and IR
             Charley's Fund Contact:
             Tracy Seckler, 413-528-5744
             Nash Avery Foundation Contact:
             Nash Avery Foundation
             Tom C. Wicka
             President and Founder

    SOURCE: CombinatoRx, Incorporated